Safety and efficacy of rituximab biosimilar (CT-P10) in systemic sclerosis: an Italian multicentre study.
Sign Up to like & getrecommendations! Published in 2020 at "Rheumatology"
DOI: 10.1093/rheumatology/keaa136
Abstract: OBJECTIVES Recent data have shown a significant efficacy of rituximab (RTX) in SSc. An RTX biosimilar (RTX-B) is a more affordable option. We assessed the safety and efficacy of an RTX-B (CT-P10) in SSc. METHODS… read more here.
Keywords: ssc patients; rtx rtx; efficacy rituximab; safety efficacy ... See more keywords